Recent developments include a $100 million U.S. rights licensing deal for ALA-002, expansion of the Nugevia™ supplement market, showcasing of the JOTROL program at industry conferences, and a reverse stock split to address Nasdaq listing compliance.

• Jupiter Neurosciences secured a $100 million term sheet for U.S. licensing rights of ALA-002, representing a major strategic transaction [N1].
• The company expanded the addressable market for its Nugevia™ supplement line with a focus on GLP-1 users, broadening potential consumer base [N2].
• Jupiter Neurosciences showcased its lead program JOTROL at the DealFlow Discovery Conference, highlighting its clinical development progress [N3].
• The company highlighted the breakthrough JOTROL™ resveratrol platform with enhanced bioavailability and therapeutic potential [N4].
• Jupiter Neurosciences launched Nugevia™ PWR, a science-driven cellular energy supplement aimed at longevity [N5].
• Annika Sörenstam was appointed as the first brand ambassador for the Nugevia™ longevity supplement line, supporting marketing efforts [N6].
• The company partnered with Catalent for production related to the Parkinson's JOTROL trial, supporting clinical development [N7].
• Jupiter Neurosciences partnered with Zina Biopharmaceuticals to launch a Phase 2a clinical trial of JOTROL in Parkinson's disease [N8].
• A 1-for-75 reverse stock split was effected on August 6, 2026, to increase the per share trading price and regain Nasdaq compliance [S2].

The company has advanced clinical programs in Parkinson's disease with partnerships supporting trial production and development. The $100 million licensing deal for ALA-002 represents a significant strategic transaction that could enhance revenue streams. Expansion of the Nugevia™ supplement market and brand ambassador initiatives may increase consumer awareness and sales. Regaining Nasdaq compliance through the reverse stock split may improve investor confidence and market liquidity.

Jupiter Neurosciences faces substantial liquidity constraints with a current ratio below 1 and no reported cash reserves, raising concerns about its ability to fund operations. Recurring net losses and negative cash flows have led management and auditors to express substantial doubt about the company's ability to continue as a going concern. Failure to regain Nasdaq listing compliance could result in delisting, reducing liquidity and investor interest. The company depends on additional financing, which may not be available on acceptable terms, posing risks to ongoing operations and development programs.

Jupiter Neurosciences' moat is based on its proprietary JOTROL™ resveratrol platform with enhanced bioavailability, which is positioned as a breakthrough therapeutic approach in neurodegenerative diseases. Strategic partnerships for clinical trials and licensing agreements, such as the $100 million U.S. rights deal for ALA-002, provide potential competitive advantages. The company's focus on longevity supplements with scientific backing and brand ambassador appointments also contribute to its market positioning. However, the company operates in a highly competitive and regulated biotech and supplement market with significant execution and financing risks.

• Liquidity and Going Concern Risk: The company has limited cash resources and a current ratio of 0.66 as of June 30, 2026, with management expressing substantial doubt about its ability to continue as a going concern without additional financing [S2].
• Nasdaq Listing Compliance Risk: Jupiter Neurosciences has received notices for non-compliance with Nasdaq's minimum bid price and market value requirements, with a deadline of August 25, 2026, to regain compliance. Failure to do so may lead to delisting and adverse effects on liquidity and capital raising [S2].
• Operational and Development Risks: The company is dependent on successful clinical trials and commercialization of its lead programs such as JOTROL™. Delays or failures in development, regulatory approvals, or market acceptance could materially impact business prospects.

• Jupiter Neurosciences, Inc. is a publicly traded company listed on Nasdaq under the ticker JUNS following a 1-for-75 reverse stock split effective August 6, 2026 [S2].
• The reverse stock split reduced outstanding shares from approximately 57.8 million to about 770,000 shares to address Nasdaq's minimum bid price requirement [S2].
• The company is focused on developing and commercializing products related to neuroscience and longevity, including the JOTROL™ resveratrol platform and the Nugevia™ supplement line [N4][N5].
• JOTROL™ is a lead program with enhanced bioavailability and therapeutic potential, currently in clinical trials for Parkinson's disease, including a Phase 2a trial in partnership with Zina Biopharmaceuticals [N8][N7].
• Jupiter Neurosciences has partnered with Catalent for production related to the Parkinson's JOTROL trial [N7].
• The company has expanded the addressable market for its Nugevia™ product line with a focus on GLP-1 users [N2].
• Jupiter Neurosciences appointed Annika Sörenstam as the first brand ambassador for the Nugevia™ longevity supplement line [N6].
• The company signed a $100 million U.S. rights deal for ALA-002, a licensing agreement that represents a significant strategic transaction [N1].
• Financial figures from the latest SEC 10-Q filing as of June 30, 2026, show quarterly revenue of $24,245 and a net loss of $2,274,397, with basic and diluted EPS of -$4.08 [S2].
• Current assets as of June 30, 2026, were $2,548,806 and current liabilities were $3,879,498, resulting in a current ratio of 0.66 and a cash ratio of 0, indicating limited liquidity [S2].
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, and the need for additional financing [S2].
• The company has received Nasdaq notices for non-compliance with minimum bid price and market value of listed securities requirements, with a compliance deadline of August 25, 2026 [S2].
• If the company fails to regain compliance with Nasdaq listing requirements, it may face delisting, which could adversely affect liquidity, investor interest, and capital raising ability [S2].